28 results

• Juvederm Lawsuit Claims Fillers Caused Facial Scarring, Disfigurement

  July 2, 2026

  Irvin Jackson

  A class action lawsuit claims the label for Juvederm cosmetic injections fails to warn patients of the risk of facial scarring and disfigurement

• CoolSculpting Lawsuit Filed Over Risk of PAH Side Effects Following Treatment

  October 16, 2024

  Irvin Jackson

  California woman indicates that areas of her stomach treated by CoolSculpting system began showing large, misshapen bulges, which required additional surgery.

• Rinvoq Lawsuit Filed Against AbbVie By Investors Over Failure to Disclose Safety Concerns

  April 14, 2022

  Irvin Jackson

  AbbVie faces a class action lawsuit by investors who say the company mislead them about the safety of Rinvoq before new warning labels for cancer and heart problems were added.

• Rinvoq Approved As Atopic Dermatitis Treatment Despite Heart, Cancer Risks

  January 19, 2022

  Irvin Jackson

  The FDA has approved Rinvoq for the treatment of atopic dermatitis despite cancer and heart problem fears.

• Despite Side Effects of Xeljanz and Rinvoq, FDA Still Approves New Indications After Updated Warnings

  December 16, 2021

  Irvin Jackson

  The FDA has granted new approvals for rheumatoid arthritis drugs Xeljanz and Rinvoq despite concerns over heart, cancer and blood clot side effects.

• Rinvoq Warning Label Updated to Add Cancer and Heart Risks Seen With Xeljanz Side Effects

  December 6, 2021

  Irvin Jackson

  Rinvoq will now carry label warnings on cancer and heart risks which were first discovered through a study of Xeljanz side effects.

• Eli Lilly-Funded Study Claims Side Effects of Olumiant Do Not Warrant Same Adverse Label Warnings as Xeljanz

  November 16, 2021

  Irvin Jackson

  A new study announced by Eli Lilly appears to suggest Olumiant, a rheumatoid arthritis drug, does not need the same label warnings for heart problems as Xeljanz, it's competitor.

• Xeljanz Heart Risks May Be Similar Across Other JAK Inhibitors Like Rinvoq, Oluminant: Study

  November 12, 2021

  Irvin Jackson

  A new study suggests the risk of heart problems linked to Xeljanz is similar across all other rheumatoid arthritis drugs belonging to the same class of medications.

• Xeljanz FDA Label Warning Update Adds Information About Risk of Cancer, Blood Clots and Heart Side Effects

  September 2, 2021

  Irvin Jackson

  The FDA is requiring new label warnings for Xeljanz and similar drugs, following a review which revealed links between increased risks of heart attacks, strokes, blood clots, and lymphomas, as well as an increased risk of lung cancer for current or former smokers.

• Experts, FDA Concerned Xeljanz Heart and Cancer Problems May Affect Similar Arthritis Drugs

  July 28, 2021

  Irvin Jackson

  Drugs in the same class as Xeljanz face increased scrutiny over concerns they may carry similar heart and cancer risks such as those suspected of plaguing the arthritis drug.